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clinical trial
Camille Roubille1, Johanne Martel-Pelletier1, Jean-Pierre Raynauld1, François Abram2, Marc Dorais3, Philippe Delorme1
and Jean-Pierre Pelletier1*Abstract
Introduction: To evaluate the impact of meniscal extrusion (Ext) on knee osteoarthritis (OA) structural progression
and on response to strontium ranelate (SrRan) treatment at 36 months in patients with (+) or without (-) Ext, in
association (+) or not (-) with bone marrow lesions (BML) in the medial compartment using X-rays (JSW) and qMRI.
Methods: Patients from the qMRI substudy of the SEKOIA trial (SrRan 1 g/day, n = 113; SrRan 2 g/day, n = 105;
placebo, n = 112) were stratified based on whether meniscal extrusion and/or BML were present or not in the
medial compartment.
Results: In the placebo group, Ext+ patients (n = 26) had more JSW loss (p = 0.002) and cartilage volume loss in the
global knee (p = 0.034) and plateau (p = 0.005), and medial compartment (p = 0.0005) than Ext- patients (n = 86).
Ext-BML+ patients (n = 18) demonstrated more JSW loss (p = 0.003) and cartilage volume loss in the global (p = 0.020)
and medial femur (p = 0.055) than Ext-BML- (n = 68). Compared to Ext+ BML- (n = 14), Ext+ BML+ patients (n = 12) had
more cartilage volume loss in the global femur (p = 0.028), with no change in JSW. The JSW loss (p = 0.0004) and cartilage
volume loss (global knee, p = 0.033, medial compartment, p = 0.0005) were greater when Ext and BML were simultaneously
present in the medial compartment. SrRan 2 g/day treatment demonstrated a reduction in OA knee structural progression
with qMRI, but not with JSW, in which less cartilage volume loss was found in the plateaus (p = 0.007) in Ext+ patients
(n = 15), and in the medial plateau (p = 0.046) in patients in whom both Ext and BML were co-localized.
Conclusion: The findings of this study are novel and could have an impact on future strategies regarding clinical trials.
Indeed, data first argue for a combined, cumulative effect of meniscal extrusion and bone marrow lesions on cartilage
loss and, secondly, they showed that SrRan may have protective effects in OA patients with meniscal extrusion as well as
when both meniscal extrusion and BML are co-localized.Introduction
Knee osteoarthritis (OA) structural changes are complex
and comprise cartilage loss as well as meniscal lesions,
including extrusion [1,2]. These are believed to not only
be responsible for disease symptoms but also to promote
cartilage degeneration and loss [3]. To date, joint space
width (JSW) loss over time is still considered the gold* Correspondence: dr@jppelletier.ca
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stated.standard to evaluate the effects of disease-modifying OA
drugs (DMOAD) [2]. However, the integrity of sur-
rounding tissues, particularly the meniscus, may affect
the reliability of such measurement [4]. Moreover, quan-
titative magnetic resonance imaging (qMRI) has been
shown to be instrumental in identifying factors predict-
ive of treatment responsiveness, such as bone marrow
lesions (BML) [2,5].
We and others have shown that the presence of severe
meniscal extrusion is predictive of knee OA structural
progression as assessed by qMRI, and a strong predictorl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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portant risk factor for OA structural progression is the
presence of BML [11,12]. Although a recent study using
semiquantitative MRI scoring for cartilage assessment
showed that the risk of cartilage loss is increased with
co-localized pathologies (meniscal extrusion (Ext) and
BML) and further increased when more than one such
pathology is present [13], these findings need further
confirmation by radiography and qMRI.
In the context of personalized management of OA, an-
other clinically relevant concern is the impact of meniscal
extrusion, alone or in conjunction with BML, on the re-
sponse to putative DMOAD treatment. This question was
raised by the findings of recent studies using qMRI, in
which patients with severe meniscal extrusion demon-
strated more severe cartilage volume loss but were also
more responsive to such treatment [14], and in a subset of
patients from the phase III knee OA trial (SEKOIA) show-
ing that Strontium ranelate (SrRan) (2 g/day) at 36-month
follow up significantly decreased cartilage volume loss in
the medial plateau in patients with BML in the medial com-
partment [15]. However, the impact of the simultaneous
presence of meniscal extrusion and BML on response to
treatment that may modify disease structural progression is
at present unknown and is an issue of great clinical interest.
To address these issues, we analyzed patients from a
sample of the phase III knee OA SEKOIA trial [16] used
in a recent qMRI study [15] and evaluated the impact of
extrusion at baseline, co-localized or not with BML in the
medial compartment, on knee OA structural progression
in the placebo group, and on response to SrRan treatment
at 36-month follow up, comparing JSW loss (radiography)
and cartilage volume loss (qMRI) in the global knee and
subregions, with emphasis on the medial compartment.
Methods
Study sample and treatment
The patient sample was as described in our recent report
[15]. Briefly, 438 patients from the three-year SEKOIA
cohort were randomized to undergo MRI examinations.
The modified intention-to-treat (mITT) sample (n =
330) included all randomized patients who received at
least one dose of SrRan and had at least two MRI exami-
nations as described (placebo, n = 112; SrRan 1 g/day,
n = 113; SrRan 2 g/day, n = 105) [15]. The protocol and
other documents of the original SEKOIA study [16] re-
lated to informed consent and investigator information
were reviewed by independent ethics committees in the
countries concerned and by the investigators and coordi-
nators in accordance with local regulatory requirements.
Written informed consent was obtained from all partici-
pants. The study was performed in accordance with the
ethical principles laid out in the Declaration of Helsinki
and is registered (ISRCTN41323372).Study design
The patients of the three groups were stratified into two
main groups based on the presence (+) or absence (-) of
Ext in the medial compartment at baseline, and further
stratified based on the presence (+) or absence (-) of BML
in the medial compartment, co-localized or not, with Ext.
This stratification was based on regrouping patients with
similar knee OA risk factors at baseline that are predictive
of structural progression. Ext was assessed using the sagit-
tal three-dimensional intermediate-weighted sequence
with fat suppression (VISTA-SPAIR), which allows for a
precise evaluation of the extent of the extrusion, and
scored as absence or presence of partial or complete ex-
trusion detected in any of the three segments of the me-
niscus as described [3,9]. BMLs were assessed with the
sagittal proton density-weighted fast spin-echo sequence
with fat suppression (PD-FSE) and evaluated as absence
or presence as described [17].
Imaging of the knee
MRI scans were performed at baseline and at 36 months
using a 1.5-Tesla scanner (Siemens, Erlangen, Germany or
General Electric, Milwaukee, WI, USA) with a dedicated
knee coil, as previously described [15]. The cartilage vol-
ume and change were measured using the proprietary soft-
ware, Cartiscope™ (ArthroLab, Montreal, QC, Canada) [18].
The minimal JSW (mm) at the narrowest point in the med-
ial tibiofemoral compartment was determined by radiog-
raphy and measured as described [15].
Symptoms
Disease symptoms were assessed at baseline as de-
scribed, using the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) question-
naire and the visual analog scale (VAS) for global knee
pain [15].
Outcomes
The first endpoint of the study was the change in JSW and
in cartilage volume in the medial compartment at
36 months in the placebo group according to the absence
or presence of Ext and/or BML in the medial compartment
at baseline. In this study, emphasis was on the assessment
of cartilage volume in the medial compartment as this area
is related to JSW measurement. The second endpoint was
to assess and compare change in the JSW and cartilage vol-
ume in the medial compartment at 36 months in the SrRan
treatment groups versus placebo, according to the presence
of Ext and/or BML in the medial compartment at baseline.
Statistical analyses
The analyses of the mITT patients (n = 330) were carried
out by imputing the missing data to the average change
recorded (mean value imputed) among patients within
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we compared the baseline demographic, clinical, and im-
aging characteristics discriminating Ext+ and Ext-, and sub-
groups BML+ and BML-, using the Kruskall-Wallis test
(non-normal distribution) for continuous variables or
the chi-square test for categorical variables. The relation-
ship between the number of co-localized factors (Ext and/
or BML) and JSW loss and cartilage volume loss in the
medial compartment at 36 months was assessed by ana-
lysis of covariance (ANCOVA) using the number of co-
localized factors in the medial compartment at baseline as
dependent variable (0 = no Ext or BML, 1 = either Ext or
BML, 2 = Ext and BML). Further comparisons between
the three treatment groups were performed using the
Kruskall-Wallis test or the chi-square test. When the
P-values were <0.10, each treatment group was further
analyzed as two-by-two comparison using the Mann-
Whitney test or the chi-square test with Bonferroni adjust-
ment. The change in JSW and cartilage volume was also
analyzed using multivariate regression models when ap-
propriate and, provided that samples were large enough,
adjusting for potential confounding factors at baseline.
Results
Study sample and baseline characteristics
Baseline characteristics of the entire mITT sample have
been previously described [15]. In this post hoc analysis,Figure 1 Study design. n, number of participants; MRI; magnetic resonan
BML, bone marrow lesions.the Ext+ group comprised 60 patients (placebo, n = 26;
SrRan 1 g/day, n = 19; SrRan 2 g/day, n = 15), and the
Ext- group, 270 patients (placebo, n = 86; SrRan 1 g/day,
n = 94; SrRan 2 g/day, n = 90) (Figure 1).
Baseline characteristics within the placebo group
In the placebo group (n = 112), demographic and clinical
characteristics were balanced between Ext+ (n = 26) and
Ext- patients (n = 86) (Table 1). However, Ext+ patients
had more severe structural disease at baseline as
assessed by radiography, showing significantly narrower
JSW and more frequent grade-3 Kellgren-Lawrence (KL)
scores. No differences between these groups were found
in cartilage volume when assessed by qMRI (Table 1).
However, there were significantly more Ext+ patients
with BML+ at baseline (Table 1).
When stratifying Ext- and Ext+ groups based on the
co-localization of BML (Table 2), the Ext-BML+
patients had higher KL grades than those without
BML. No differences were found in JSW or cartilage
volume between groups. Yet, WOMAC total score,
function and pain were higher in the Ext+ BML- group
than in the Ext+ BML+ group (Table 2). Interestingly,
although not statistically significant, cartilage volume
in all knee regions studied was lower in the Ext+
BML+, and compared to the Ext+ BML- group, nu-
merical trends were found in the medial compartmentce imaging; mITT, modified intention-to-treat; Ext, meniscal extrusion;
Table 1 Baseline demographic, clinical, and imaging
characteristics of the placebo group according to the
absence or presence of meniscal extrusion
Ext- (n = 86) Ext+ (n = 26) P-value
Demographic and clinical
Age, years 62 ± 8 65 ± 8 0.078
Female, n (%) 57 (66%) 19 (73%) 0.515†
Body mass index, kg/m2 30 ± 4 29 ± 6 0.275
WOMAC
Pain (0 to 100) 37.7 ± 21.9 40.9 ± 20.0 0.340
Function (0 to 100) 39.5 ± 22.4 38.3 ± 22.7 0.762
Stiffness (0 to 100) 41.9 ± 24.5 46.4 ± 19.4 0.403
Total (0 to 300) 120.6 ± 65.0 127.1 ± 56.6 0.654
VAS pain (0 to 100 mm) 48.5 ± 25.2 54.3 ± 18.8 0.199
Imaging
Kellgren-Lawrence score, n (%) 0.002†
Grade 1 - -
Grade 2 64 (74%) 11 (42%)
Grade 3 22 (26%) 15 (58%)
Joint space width, mm 3.61 ± 0.77 3.15 ± 0.51 0.004
Presence of BML in the medial
compartment, n (%)
18 (21%) 12 (46%) 0.011†
MRI, mm3
Global knee 11256 ± 2968 10479 ± 2243 0.395
Femur 7773 ± 2139 7398 ± 1465 0.697
Plateau 3483 ± 897 3081 ± 830 0.109
Medial compartment 5324 ± 1435 5089 ± 1020 0.682
Medial femur 3763 ± 1023 3619 ± 689 0.817
Medial plateau 1562 ± 452 1470 ± 360 0.608
Results are shown as mean ± SD unless otherwise indicated. †P-values
obtained using the chi-square test. All other P-values were obtained using the
Kruskal-Wallis test. Statistically significant P-values are in bold. Ext, meniscal
extrusion; n, number of participants; WOMAC, Western Ontario and McMaster
Universities Osteoarthritis Index (each subscale, 100 = worst score; total scale,
300 = worst score). ; VAS, visual analog scale (0 mm= no pain, 100 mm= most
severe pain); MRI, magnetic resonance imaging; BML, bone marrow lesions.
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+ BML+ patients had the narrowest JSW among all
subgroups, but the difference compared to Ext+ BML-
did not reach statistical significance.
Baseline characteristics within the treatment groups
The SrRan 1 g/day, 2 g/day and placebo groups were
fairly balanced at baseline except for age in the Ext- pa-
tients and, in the Ext+ patients, gender and lower global
knee cartilage volume in the placebo group (Table 3).
Co-localization or not with BML revealed no differ-
ences except for body mass index (BMI) and JSW in the
Ext+ BML+ patients, in which a higher BMI was found
in the SrRan 1 g/day group versus placebo (P = 0.003),and less JSW in the SrRan 1 g/day group versus placebo
(P = 0.015) (data not shown).
Change in JSW and cartilage volume at 36 months in the
placebo group
Compared to Ext-, the Ext+ patients demonstrated sig-
nificantly more JSW loss as analyzed using univariate
analysis (Table 4). This result was further confirmed in
multivariate regression (P = 0.021) (data not shown) ad-
justed for the features that were different at baseline (see
Table 1): KL grade, presence of BML, and JSW.
Moreover, the Ext+ patients had significantly more car-
tilage volume loss in the global knee and plateau, and in
the medial compartment including both femur and plat-
eau (Table 4). In multivariate analysis adjusted as de-
scribed above, a numerical trend (P = 0.12) toward more
cartilage volume loss in the medial compartment in
Ext+ patients was found with statistical significance at the
medial femur (P = 0.053) (data not shown). Data further
showed that the Ext+ patients also had more cartilage vol-
ume loss in the lateral plateau than the Ext- patients
(-10.90% ± 5.08 versus -8.57% ± 4.95, P = 0.011).
Evaluation of the impact of co-localization of Ext and
BML on change in JSW and cartilage volume revealed
that in the Ext- group, BML+ patients had significantly
more loss of JSW and of cartilage volume in the global
and medial femur with a numerical trend in the medial
compartment compared with BML- patients (Table 4).
Of note, although not reaching statistical significance,
Ext-BML+ patients showed higher cartilage volume loss
(about 55%) in the medial plateau than the Ext-BML-
patients.
In the Ext+ group, while BML+ and BML- patients were
not different with regard to JSW loss, BML+ patients
demonstrated more cartilage volume loss in the global
femur with trends in the global knee and in the medial
compartment (Table 4). Interestingly, assessment of JSW
loss and cartilage volume loss in the medial compartment
according to the number of co-localized factors (Ext ±
BML) at baseline (Table 5) revealed that loss of both JSW
and cartilage volume in the global knee and all subregions
studied except the global femur, significantly increased
with an additional co-localized factor (that is, from no fac-
tors to one factor, or from one factor to two factors).
Hence, JSW and cartilage volume loss were greater when
Ext and BML were co-localized.
Effect of SrRan treatment at 36 months
Because the main aim of this work was to understand
the various effects of Ext and BML on JSW and cartilage
volume changes, the evaluation of the response to SrRan
treatment was performed on the Ext+ subjects only
(Table 6). Data revealed no statistically significant differ-
ence between treatment groups for JSW loss. However,
Table 2 Baseline demographic, clinical, and imaging characteristics of the placebo group according to absence or
presence of meniscal extrusion and bone marrow lesions (modified intention-to-treat sample, n = 330)
Ext- (n = 86) Ext+ (n = 26)
BML- (n = 68) BML+ (n = 18) P-value BML- (n = 14) BML+ (n = 12) P-value
Demographic and clinical
Age, years 61 ± 7 64 ± 10 0.493 65 ± 7 65 ± 10 >0.999
Female, n (%) 47 (69%) 10 (56%) 0.279† 9 (64%) 10 (83%) 0.275†
Body mass index, kg/m2 30 ± 4 30 ± 3 0.824 31 ± 7 27 ± 3 0.116
WOMAC
Pain (0 to 100) 37.4 ± 22.7 39.2 ± 19.0 0.587 48.5 ± 19.2 32.8 ± 18.2 0.053
Function (0 to 100) 40.7 ± 22.5 35.5 ± 22.3 0.449 46.6 ± 22.6 28.7 ± 19.5 0.021
Stiffness (0 to 100) 41.4 ± 26.3 43.7 ± 16.3 0.834 50.8 ± 17.5 41.4 ± 21.1 0.208
Total (0 to 300) 120.9 ± 67.5 119.6 ± 55.8 0.871 149.4 ± 51.5 102.9 ± 53.5 0.024
VAS pain (0 to 100 mm) 50.4 ± 25.6 41.3 ± 23.1 0.126 56.9 ± 17.2 51.3 ± 20.8 0.425
Imaging
Kellgren-Lawrence, n (%) 0.039† 0.391†
Grade 1 - - - -
Grade 2 54 (79%) 10 (56%) 7 (50%) 4 (33%)
Grade 3 14 (21%) 8 (44%) 7 (50%) 8 (67%)
Joint space width, mm 3.68 ± 0.74 3.37 ± 0.85 0.125 3.28 ± 0.55 2.99 ± 0.42 0.207
MRI, mm3
Global knee 11247 ± 3151 11292 ± 2218 0.622 10930 ± 1749 9952 ± 2694 0.190
Femur 7725 ± 2264 7956 ± 1621 0.321 7748 ± 1225 6989 ± 1664 0.129
Plateau 3522 ± 943 3336 ± 700 0.803 3182 ± 591 2962 ± 1060 0.456
Medial compartment 5334 ± 1525 5288 ± 1065 0.746 5355 ± 841 4479 ± 1155 0.095
Medial femur 3766 ± 1089 3752 ± 750 0.549 3818 ± 550 3388 ± 783 0.068
Medial plateau 1568 ± 471 1537 ± 384 >0.999 1538 ± 336 1390 ± 384 0.247
Results are shown as mean ± SD unless otherwise indicated. †P-values obtained using the chi-square test. All other P-values were obtained using the Kruskal-Wallis test.
Statistically significant P-values are in bold. Ext, meniscal extrusion; n, number of participants; BML, bone marrow lesions; WOMAC, Western Ontario and McMaster
Universities Osteoarthritis Index (each subscale, 100 =worst score; total scale, 300 =worst score); VAS, visual analog scale (0 mm= no pain, 100 mm=most severe pain);
MRI, magnetic resonance imaging.
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cartilage volume loss in the global plateau in both
univariate (P = 0.007, Table 6) and multivariate analyses (P
= 0.014, data not shown), the latter adjusted for gender and
cartilage volume which were significantly different at base-
line and considered as potential confounding factors. More-
over, although SrRan 2 g/day markedly decreased (by about
66%) the cartilage volume loss in the medial plateau, the
difference did not quite reach statistical significance but
yielded a numerical trend (P = 0.081, Table 6), probably due
to the relatively small number of patients in each group.
Interestingly, the Ext+ patients demonstrated that both
SrRan 1 g/day and 2 g/day significantly reduced the cartil-
age volume loss in the lateral plateau (-7.29% ± 3.86, P =
0.019 and -6.46% ± 3.93, P = 0.014, respectively) compared
to placebo (-10.90% ± 5.08).
Further analysis in Ext+/BML- patients showed no sig-
nificant difference between SrRan and placebo with regard
to the loss of JSW and of cartilage volume. Althoughsubgrouping results in a lower number of patients in each
group, interesting data were found only for qMRI when Ext
and BML were co-localized. Hence, Ext+ BML+ patients in
the SrRan 1 g/day group demonstrated a significant reduc-
tion in cartilage volume loss in the global plateau (P =
0.017) and in the SrRan 2 g/day group in the medial plateau
(P = 0.046), compared with placebo (data not shown).
Discussion
The present study aimed at expanding our previous find-
ings [15] and to evaluate the impact of meniscal extrusion,
co-localized or not with BML in the medial compartment,
on the natural structural progression of knee OA using the
placebo group, and on the response to SrRan by comparing
the loss of JSW and of cartilage volume.
In the placebo group, the proportion of patients with
meniscal extrusion was lower than in some studies [9,18],
reinforcing our assumption in the previous report on this
trial [15] that this cohort had a more moderate degree of
Table 3 Baseline demographic, clinical, and imaging characteristics in the treatment groups according to the absence














Ext- n = 94 n = 90 n = 86
Demographic and clinical
Age, years 60 ± 7 63 ± 7 62 ± 8 0.045* 0.961** 0.548**
Female, n (%) 63 (67%) 61 (68%) 57 (66%) 0.978†
Body mass index, kg/m2 30.0 ± 5.0 29.8 ± 9.9 32.4 ± 8.1 0.187*
WOMAC
Pain (0 to100) 40 ± 20 44 ± 21 38 ± 22 0.107*
Function (0 to 100) 42 ± 21 42 ± 24 40 ± 22 0.732*
Stiffness (0 to 100) 46 ± 23 48 ± 26 42 ± 24 0.294*
Total (0 to 300) 130 ± 59 132 ± 64 121 ± 65 0.446*
VAS pain (0 to 100 mm) 50 ± 22 54 ± 24 48 ± 25 0.204*
Imaging
Kellgren-Lawrence, n (%) 0.943†
Grade 1 - - -
Grade 2 71 (76%) 66 (73%) 64 (74%)
Grade 3 23 (24%) 24 (27%) 22 (26%)
Joint space width, mm 3.61 ± 0.82 3.67 ± 0.81 3.61 ± 0.77 0.707*
Presence of BML, n (%) 23 (24%) 20 (22%) 18 (21%) 0.847†
MRI, mm3
Global knee 11256 ± 2920 11520 ± 3344 11256 ± 2968 0.911*
Femur 7759 ± 2121 8000 ± 2286 7773 ± 2139 0.750*
Plateau 3497 ± 886 3520 ± 1158 3483 ± 897 0.855*
Medial compartment 5391 ± 1374 5547 ± 1577 5325 ± 1435 0.655*
Medial femur 3797 ± 1020 3937 ± 1098 3763 ± 1023 0.540*
Medial plateau 1594 ± 405 1610 ± 541 1562 ± 452 0.726*
Ext+ n = 19 n = 15 n = 26
Demographic and clinical
Age, years 61 ± 6 61 ± 8 65 ± 8 0.228*
Female, n (%) 7 (37%) 9 (60%) 19 (73%) 0.051† 0.045** >0.999**
Body mass index, kg/m2 30.7 ± 4.7 32.2 ± 6.4 29.3 ± 6.0 0.164*
WOMAC
Pain (0 to100) 50 ± 21 50 ± 16 41 ± 20 0.320*
Function (0 to 100) 47 ± 21 45 ± 19 38 ± 23 0.593*
Stiffness (0 to 100) 52 ± 24 57 ± 17 46 ± 19 0.252*
Total (0 to 300) 147 ± 58 153 ± 46 127 ± 57 0.394*
VAS pain (0 to 100 mm) 56 ± 19 58 ± 19 54 ± 19 0.837*
Imaging
Kellgren-Lawrence, n (%) 0.158†
Grade 1 - - -
Grade 2 6 (32%) 2 (13%) 11 (42%)
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Table 3 Baseline demographic, clinical, and imaging characteristics in the treatment groups according to the absence
or presence of meniscal extrusion (Ext) (Continued)
Grade 3 13 (68%) 13 (87%) 15 (58%)
Joint space width (mm) 2.91 ± 0.75 2.80 ± 0.35 3.15 ± 0.51 0.110*
Presence of BML, n (%) 8 (42%) 3 (20%) 12 (46%) 0.232†
MRI, mm3
Global knee 12345 ± 3367 12838 ± 2972 10479 ± 2243 0.032* 0.193** 0.050**
Femur 8497 ± 2192 8962 ± 2100 7398 ± 1465 0.044* 0.274** 0.062**
Plateau 3848 ± 1281 3875 ± 1051 3081 ± 830 0.029* 0.100** 0.071**
Medial compartment 5707 ± 1520 5845 ± 1305 5089 ± 1020 0.208*
Medial femur 4013 ± 958 4136 ± 945 3619 ± 689 0.176*
Medial plateau 1695 ± 624 1708 ± 397 1470 ± 360 0.295*
Results are shown as mean ± SD unless otherwise indicated. *P-values assessed using the Kruskal-Wallis test; **P-values assessed using the **Mann-Whitney test with
Bonferroni adjustment for multiple comparisons; P-values assessed using the †chi-square test for categorical variables. Statistically significant P-values are in bold. Ext,
meniscal extrusion; n, number of participants; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index (each subscale, 100 =worst score; total scale,
300 =worst score); VAS, visual analog scale (0 mm= no pain, 100 mm=most severe pain); BML, bone marrow lesions MRI, magnetic resonance imaging.
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global and medial cartilage volume changes in the patients
with meniscal extrusion are in line with the findings of
previous studies [2,9]. Showing that meniscal extrusion was
associated with more rapid progression of knee OA
as evaluated by both radiography and qMRI met ourTable 4 Joint space width loss and cartilage volume loss at 3
co-localization of meniscal extrusion and bone marrow lesion
Ext- (n = 86)
Joint space width loss
mm -0.35 ± 0.61
% -10.36 ± 20.10
MRI (%)
Global knee -6.70 ± 2.78
Femur -6.15 ± 3.29
Plateau -7.80 ± 5.05
Medial compartment -7.60 ± 4.63
Medial femur -7.90 ± 4.76
Medial plateau -6.77 ± 7.52
BML- (n = 68) BML+ (n = 18)
Joint space width loss
mm -0.23 ± 0.55 -0.77 ± 0.68
% -5.79 ± 15.35 -27.64 ± 26.29
MRI (%)
Global knee -6.75 ± 2.81 -6.50 ± 2.71
Femur -6.39 ± 3.36 -5.26 ± 2.92
Plateau -7.38 ± 4.15 -9.40 ± 7.49
Medial compartment -7.08 ± 4.33 -9.57 ± 5.29
Medial femur -7.54 ± 4.90 -9.26 ± 4.03
Medial plateau -5.79 ± 5.68 -10.46 ± 11.70
Results for cartilage volume loss are percentage (%) of change expressed as mean ±
P-values are in bold. Ext, meniscal extrusion; n, number of participants; MRI, magnefirst outcome, further confirming previous results
[3,8-11,13,14]. These data are also consistent with previous
reports [15,19,20] of a positive correlation between loss of
JSW and of cartilage volume in the medial compartment.
Meniscal extrusion has been formerly found to con-
tribute to joint space narrowing [21,22] and it has been6 months in the placebo group according to the
s in the medial compartment at baseline
Ext+ (n = 26) P-value
-0.76 ± 0.67 0.002
-23.24 ± 19.23 0.0008
-8.02 ± 3.28 0.034
-7.28 ± 2.91 0.171
-10.01 ± 5.79 0.005
-10.40 ± 4.23 0.0005
-10.89 ± 3.19 0.0002
-9.07 ± 8.74 0.012
P-value BML- (n = 14) BML+ (n = 12) P-value
0.003 -0.88 ± 0.82 -0.61 ± 0.43 0.455
0.002 -25.44 ± 22.79 -20.68 ± 14.62 0.589
0.227 -6.89 ± 3.70 -9.33 ± 2.19 0.066
0.020 -6.16 ± 2.97 -8.57 ± 2.32 0.028
0.162 -8.67 ± 7.12 -11.57 ± 3.37 0.093
0.090 -9.69 ± 5.50 -11.22 ± 1.90 0.103
0.055 -10.72 ± 4.08 -11.08 ± 1.86 0.339
0.185 -7.04 ± 10.97 -11.45 ± 4.47 0.155
SD. P-values were assessed using the Kruskal-Wallis test. Statistically significant
tic resonance imaging; BML, bone marrow lesions.
Table 5 Impact of co-localized factors* present in the
medial compartment at baseline on loss of joint space
width and of cartilage volume at 36 months in the
placebo group
Loss of joint space width and
cartilage volume linked to
addition of one co-localized
factor
P-value




Global knee -0.86 0.033
Femur -0.53 0.239
Plateau -1.97 0.007
Medial compartment -2.22 0.0005
Medial femur -1.95 0.002
Medial plateau -2.93 0.006
P-values were assessed with analysis of covariance (ANCOVA) using the number
of co-localized factors in the medial compartment at baseline as the dependent
variable. Statistically significant P-values are in bold. *Co-localized factors:
0 = neither bone marrow lesions nor meniscal extrusion, 1 = either meniscal
extrusion or bone marrow lesions, 2 = meniscal extrusion and bone marrow
lesions. MRI, magnetic resonance imaging.
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thinning of articular cartilage, is involved [4,21]. In this
study, data demonstrated that the cartilage volume loss was
factual, reinforcing the causal relationship between menis-
cal extrusion and cartilage loss [7,23-25]. The finding that
patients with meniscal extrusion had more cartilage volume
loss in the lateral plateau, in addition to being an important
add-on to radiographic data showing that meniscal extru-
sion in the medial compartment could not only induce
more cartilage volume loss in the ipsilateral compartmentTable 6 Loss of joint space width and of cartilage volume at 3
extrusion
SrRan 1 g/day SrRan 2 g/day Placebo
n = 19 n = 15 n = 26
Joint space width loss
mm -0.46 ± 0.45 -0.41 ± 0.42 -0.76 ± 0
% -18.54 ± 19.69 -14.67 ± 15.69 -23.24 ±
MRI (%)
Global knee -7.66 ± 2.10 -6.67 ± 2.56 -8.02 ± 3
Femur -7.70 ± 2.66 -6.98 ± 4.26 -7.28 ± 2
Plateau -7.61 ± 3.79 -5.74 ± 3.54 -10.01 ±
Medial compartment -10.29 ± 3.68 -9.14 ± 3.27 -10.40 ±
Medial femur -11.17 ± 4.25 -10.72 ± 5.36 -10.89 ±
Medial plateau -8.13 ± 5.98 -4.90 ± 5.19 -9.07 ± 8
Results for cartilage volume loss are percentage (%) of change expressed as mean ± SD
**Mann-Whitney test with Bonferroni adjustment. Statistically significant P-values are in
resonance imaging.but also act in the contralateral one, suggests a triggering of
pathways leading to cartilage damage in the whole joint.
One may argue that meniscal extrusion likely generates
subchondral bone remodeling and BML, which subse-
quently lead to cartilage loss [25]. However, given that the
association between meniscal extrusion and JSW loss
remained significant after adjusting for the presence of
BML at baseline, meniscal extrusion in itself seems to inde-
pendently impact the structural progression.
Rather than a greater impact of meniscal extrusion on
BML or the reverse (BML on the extrusion), the literature
indicates that the co-localization of these lesions is of
greater importance for knee OA structural progression
[26,27]. Here, only data with qMRI agree with this state-
ment. While the presence of BML in patients without
meniscal extrusion was a risk factor for progression as
assessed by either JSW or cartilage volume, in patients with
meniscal extrusion the presence of BML revealed no differ-
ence in JSW loss, but with qMRI, in addition to significant
results in the global femur, statistical trends were found for
change in cartilage volume in the global knee and plateau,
and medial compartment. These data thus suggest that the
JSW loss measurement is less sensitive than qMRI in evalu-
ating the added impact of BML on OA structural progres-
sion. However, with regard to the radiographic data, one
must take into account that this is a technique of low sensi-
tivity and that the small number of patients in the sub-
groups may have reduced the strength of the analysis and
explain the non-significant difference. Nevertheless, a cu-
mulative negative impact of the presence of meniscal extru-
sion and BML at baseline on the loss of JSW and of
cartilage volume in the medial compartment was demon-
strated by covariance analyses showing that JSW loss was
0.31 mm and cartilage volume loss 2.22% per additional6 months in treatment groups in patients with meniscal









5.79 0.003* 0.070** 0.007**
4.23 0.119*
3.19 0.290*
.74 0.048* 0.708** 0.081**
. *P-values assessed using the Kruskal-Wallis test; P-values assessed using the
bold. SrRan, strontium ranelate; n, number of participants; MRI, magnetic
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an association using qMRI, but confirmed data from semi-
quantitative MRI showing that the risk of cartilage damage
further increases when more than one associated co-
localized pathology (meniscal extrusion, meniscal damage,
BML) was present [13]. The present findings thus suggest
that the presence of both meniscal extrusion and BML rep-
resent an additive risk for disease structural progression.
The higher level of symptoms (WOMAC pain, func-
tion) in the patients with meniscal extrusion but without
BML compared to those with BML is intriguing. The ex-
tent to which BML contributes to knee OA symptoms in
comparison to meniscal extrusion is still largely un-
known. Although more extensive work needs to be done
in order to answer this most relevant question, the data
from a recent study [28] indicating that meniscal extru-
sion is the knee OA structural change most commonly
associated with severe knee OA symptoms as well as the
presence of neuropathic pain, may provide some explan-
ation to the present finding.
With respect to the role of meniscal extrusion on the
response to treatment, SrRan at 2 g/day significantly re-
duced the cartilage volume loss in the plateaus and in
the medial plateau in the patients with both meniscal ex-
trusion and BML. In addition to previous data showing
that SrRan at 2 g/day can reduce cartilage volume loss
in the medial plateau in patients with BML [15], data
from this study suggest that SrRan may have structural
protective effects in patients with both BML and menis-
cal extrusion, a condition which represents an even
higher risk for more rapid structural disease progression
[11,12,17,29]. The finding that in patients with meniscal
extrusion, SrRan also reduced cartilage volume loss in
the lateral plateau, where few or no BML were found
[15], is interesting and reinforces findings that SrRan has
a direct protective effect on cartilage loss [30,31] in
addition to its impact on BML. This is supported by a
previous report in a dog experimental OA model (anter-
ior cruciate ligament model) showing that the protective
effect of SrRan was associated with a reduction in the
levels of pro-catabolic factors such as proteases and cy-
tokines (IL-1β) in the diseased tissues [31]. Based on the
present results, it can also be hypothesized that SrRan
may protect against cartilage loss by both reducing BML
and targeting the cartilage damage triggered by meniscal
extrusion. In support of this hypothesis are the findings
of a reduction in cartilage volume loss in patients with
co-localized meniscal extrusion and BML. Together, the
previous [15] and present data support a structural pro-
tective property of SrRan in patients with BML and
meniscal extrusion in the medial compartment. These
are clinically relevant, as cartilage volume loss in the
medial compartment has been shown to be the most
predictive of total knee replacement [2]. These resultsalso support the added benefit of using qMRI as an al-
ternative to radiography for the evaluation of putative
DMOAD agents, especially in patients with less ad-
vanced disease [32] and provide important new insight
into the role played by the concomitant risk factors
(meniscal extrusion and BML) in the response of pa-
tients to OA treatments [2,14].
This study has limitations, the main one being the
relatively small number of patients with meniscal extru-
sion, especially after stratification based on the co-
localization of BML. In addition, the possible role of
some other confounding factors, such as knee mal-
alignment and prior meniscal resections, could not be
evaluated as the information was not available. A com-
plementary and interesting research question that could
be addressed in further work is the assessment of bone
area, which is also a potential confounding factor. Fur-
ther MRI studies with a larger number of patients will
be needed before any firm conclusions can be made, par-
ticularly with regard to the effect of SrRan on disease
structural progression.
With regard to safety concerns, as reported in the ori-
ginal SEKOIA study [16,33], the number of treatment-
emergent and serious treatment-emergent adverse events
for SrRan 1 g/day, SrRan 2 g/day and placebo groups was
similar between groups (85.8%, 87.9% and 86.5%, and
17.0%, 16.5% and 17.4%, respectively). No cases of drug re-
action with eosinophilia and systemic symptoms, Stevens-
Johnson syndrome, or toxic epidermal necrolysis were
reported. Notably, because SrRan was found to be associ-
ated with an increased risk of myocardial infarction (MI)
in osteoporosis trials, the European Medicine Agency de-
fined new cardiovascular contraindications to SrRan. In
the SEKOIA trial, five cases of serious MI were reported
in the SrRan 2 g/day group, one case in the SrRan 1 g/day
group, and in the placebo group, in patients with major
cardiovascular risk factors or comorbidities. However,
when applying a posteriori the newly defined contraindica-
tions of the European Medicine Agency to the SEKOIA
population, the number of MIs was comparable between
the three treatment groups: one event in the SrRan 1 g/
day group, two in the SrRan 2 g/day group and one in the
placebo group [33]. In any case, based on the current
safety evidence, and consistent with the precautionary
principle, SrRan cannot currently be recommended as a
first-line DMOAD in knee OA patients.
Conclusion
This study is complementary to the previous publication
[15] and underlines the relevance of stratifying patients ac-
cording to the absence or presence of meniscal extrusion.
The results of the study are of great importance from two
different perspectives: first, they argue for a combined, cu-
mulative effect of meniscal extrusion and subchondral
Roubille et al. Arthritis Research & Therapy  (2015) 17:82 Page 10 of 11bone remodeling on cartilage damage and, second, they
show that SrRan may have protective effects in knee OA
patients with meniscal extrusion, even when co-localized
with BML. Our findings are novel and could have an im-
pact on strategies for the conduct of future trials, as well
as supporting further research on potential structural ef-
fects of other bone anti-remodelling medications. This
study also highlights that the response to treatment of
knee OA patients is a complex issue, as it can be greatly
influenced by the presence or absence of risk factors asso-
ciated with disease structural progression.
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